ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ALVO / news
MAZE (37) REPL (50) VIR (40) MESO (51) ⌘ Pro Terminal →

Why ALVO Stock dropped -3.66% Today — RQD Quant Desk Flash

$4.48 -3.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.44

Alvotech (ALVO) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.75B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALVO Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Alvotech (NASDAQ: ALVO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $4.48 (-3.66% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ALVO ranks #241 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALVO compare to MAZE and REPL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALVO carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MAZE (Maze Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, ALVO leads on earnings multiple (N/A) while MAZE leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALVO?
▼

For Alvotech (ALVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #241 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $4.44 (-0.85%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 1.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510052
Quant Analyst Panel Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D · Rk C
Cash (12)Whales (6)SEC (13)Macro (12)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE ALVO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALVO)Realized 20D OHLCV Swing Band: ±10.1%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY ALVO SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL Trailing 12 Months: 1.2% FCF Margin ($49.0M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
60
Grade C$5.17-0.8% Next Q
Q2 (-2Q)
57
Grade C$5.13-3.7% Next Q
Q3 (-1Q)
55
Grade C$4.94-9.3% Next Q
Current
52
Grade D+$4.48-1.1% Hist 90D α
Trajectory: C (60) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALVO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALVO currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.30) and Max Pain ($4.70) forces dealer call-delta covering toward $6.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALVO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALVO Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why ALVO Stock dropped -3.66% Today — RQD Quant Desk Flash

Alvotech (ALVO) dropped -3.66% to $4.48, trading at 43% of its 52-week range ($2.94 – $6.53). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 43% of its 52-week range ($2.94 – $6.53) with RSI-14 at 37.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±10.1% around $4.48 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $49.0M annual free cash flow.
Live ALVO Headlines & Catalysts
MARKET WIREInvesting.com • 2d ago
Why is Alvotech stock surging today?

Investing.com report covering Alvotech (ALVO) market action, institutional positioning, and fundamental catalysts.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALVO)

  • ✓Walkthrough of ALVO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALVO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +28.00%▲ ASCENDING CHANNEL
2026-11-04O $4.65H $4.65L $4.48C $4.48VOL 1.55M
RES: $7.06SUP: $3.25SMA50: $5.30SMA200: $4.20
$6.78$5.74$4.70$3.66$2.62RES $7.06SUP $3.25$4.482026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALVO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALVO Butterfly Map → + Track ALVO →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALVO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALVO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALVO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALVO)

Health Care Rank #241 of 1015 ⚔️ MAZE vs ALVO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALVO vs. MAZE, REPL, VIR, MESO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Alvotech (ALVO) ranks #241 by composite RQD confidence (52/100, grade D+) and #271 by equity capitalization ($1.75B). Within this direct 5-issuer industry benchmark cohort, ALVO leads on earnings valuation at N/A trailing P/E, while MAZE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ALVO currently leads its immediate peer cohort in composite quantitative strength at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALVO ACTIVE
Alvotech
D+ 52/100 — — — -3.66% $1.75B Benchmark Subject
MAZE
Maze Therapeutics Inc.
D- 37/100 — — -35.0% -3.53% $1.69B /maze-vs-alvo →
REPL
Replimune Group Inc.
D 50/100 — — -35.0% +10.68% $1.85B /repl-vs-alvo →
VIR
Vir Biotechnology Inc.
D- 40/100 — 96.0% -35.0% -2.65% $1.88B /vir-vs-alvo →
MESO
Mesoblast Limited
D 51/100 — — — -4.09% $1.89B /meso-vs-alvo →

2. ALVO Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Alvotech (ALVO) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $1.75B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. ALVO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALVO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Alvotech (NASDAQ: ALVO) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $4.48 (-3.66% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ALVO ranks #241 in composite RQD confidence.

How does ALVO compare to MAZE and REPL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ALVO carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MAZE (Maze Therapeutics Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B) and REPL (Replimune Group Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $1.85B). Among the 5-stock peer group, ALVO leads on earnings multiple (N/A) while MAZE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALVO?

For Alvotech (ALVO), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #241 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALVO trading relative to its 50-day, 200-day, and 52-week technical levels?

ALVO last traded at $4.48 (-3.66% on volume of 1,552,861 shares), positioning the stock -15.47% below its 50-day simple moving average ($5.30) and +6.67% above its 200-day simple moving average ($4.20). Across its 52-week range of $2.94 to $6.53, ALVO sits at the 42.9% percentile with a 14-day RSI of 37.8 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($4.03 to $4.93).

Direct Sub-Reports: ALVO RQD Cockpit ALVO 12M Forecast ALVO Earnings & Move ALVO Dividends & DRIP ALVO Insiders & 13F ALVO Whale Options ALVO Profit Sankey ALVO News & Why
ROARABLE RATING BRIEF • RQD 52/100 (D+) ✓ SEC XBRL & RQD VERIFIED

ALVO — Alvotech: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alvotech (ALVO) earns a live Roarable RQD composite score of 52/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $4.48 (-3.66% 1D, market capitalization $1.75B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alvotech (ALVO) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry..9B. — for the remaining business model details.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 52/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $2.94 – $6.53 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only qualitative linkage in the source data is the news reference to U.S.

  • Key Question #1: Can ALVO sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $6.53 52-week high?
  • Key Question #3: How sensitive is ALVO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ALVO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alvotech (ALVO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALVO Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALVO Bull vs. Bear Conversation Board — What's Your Call at $4.48?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALVO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ALVO:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $5.67 (+21.9%)
📌 Pinned Debate

ALVO (D+ • RQD 52/100) operating leverage in Biotechnology: Biological Products (No Diagnostic Substances) is mispriced at $4.65

Picked up a starter position in ALVO in my $100K Virtual Cash book at $4.65. ALVO (D+ • RQD 52/100) operating leverage in Biotechnology: Biological Products (No Diagnostic Substances) is mispriced at $4.65. Trading inside a $2.94–$6.53 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

EarningsSniper 🐂 BULL

Both sides have a point here — ALVO's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $3.58 (-23.0%)
Spot @ $4.65

The RQD cash engine pillar scores 12 of 20 with ROIC at 0% and FCF yield at 0%, and no financials are provided to show cash generation.

Careful chasing ALVO at $4.65. The RQD cash engine pillar scores 12 of 20 with ROIC at 0% and FCF yield at 0%, and no financials are provided to show cash generation.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $3.58 on multiple compression.

LIVE TAPE